NCT02982902View on ClinicalTrials.gov

T Cell Therapy of Opportunistic Cytomegalovirus Infection

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantOpportunistic Infections
Interventions
BIOLOGICAL

CMV specific adoptive t-cells

It is expected that the cell dose will be in the range of 10\^3 - 10\^5 virus - specific, antigen selected T cells per kg of recipient weight.

Trial Locations (1)

44106-5065

RECRUITING

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Mari Dallas

OTHER